Del Labs
This article was originally published in The Tan Sheet
Executive Summary
Net sales jumped 14.6% to $87.9 mil. in Q2, primarily driven by "continued growth" in Orajel line, cosmetics segment, firm says. Net income for quarter was $3.3 mil., up 74% compared to earnings of $1.9 mil. last year. Six-month sales totaled $160.7 mil., rising 11.4% over prior-year period. Orajel Multi Action Cold Sore Medicine shipped in June, along with new products in Dermarest Psoriasis line; TV ads slated to break in September (1"The Tan Sheet" May 7, p. 5)
You may also be interested in...
Orajel, Dermarest Line Extension Ad Support Slated For September
Del Laboratories will promote its new Orajel Multi Action Cold Sore Medicine by offering a $3 rebate to any consumer who mails the company proof-of-purchase for any cough/cold product.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands